This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Laragh, J. H. Articles by Sealey, J. E. Search for Related Content PubMed PubMed Citation Articles by Laragh, J. H. Articles by Sealey, J. E.

(Hypertension. 2001;37:806.)
© 2001 American Heart Association, Inc.

Scientific Contributions

K⁺ Depletion and the Progression of Hypertensive Disease or Heart Failure

The Pathogenic Role of Diuretic-Induced Aldosterone Secretion

John H. Laragh; Jean E. Sealey

From the Cardiovascular Center, Weill Medical College of Cornell University, New York, NY.

Correspondence to Dr John Laragh, Cardiovascular Center, Weill Medical College of Cornell University, 1300 York Ave, Room A-863, New York, NY 10021.

Key Words: potassium • hypertension • heart failure • aldosterone • spironolactone

	Introduction

 
After the introduction of chlorothiazide in 1958,¹ as the first of many sulfonamide thiazide diuretics, these orally active diuretics rapidly became the cornerstone for treatment of patients with congestive heart failure (CHF) and other edematous states. These diuretics were also widely adopted for primary or adjuvant antihypertensive drug therapy. Since the beginning, it was recognized that such natriuretic-diuretic therapy in both of these disorders is regularly accompanied by demonstrable body potassium and magnesium deficiencies, often reflected by significant, albeit generally mild, observed decrements in plasma K⁺ and Mg²⁺ levels. But because no particular problems were recognized with broad use of these diuretics, over the years physicians became increasingly sanguine about their occurrence. Accordingly, thiazide diuretics and then, beginning in 1966, the similar but more powerful loop diuretics (eg, furosemide) also became broadly used as primary or adjuvant treatments for high blood pressure and for the edematous state of CHF, cirrhosis with ascites, and nephrotic syndrome.

	Superior Features of Spironolactone Over Sulfonamide Diuretics for Treating Hypertension or CHF

 
The first selective aldosterone receptor antagonist, spironolactone (Aldactone), was introduced in clinical medicine in 1958.² By blocking the action of aldosterone, it proved to be a potent natriuretic-diuretic and K⁺-retaining agent. Thus, it produced diuresis and weight loss with no loss of K⁺ or Mg²⁺, something our group views as a great conceptual therapeutic advantage over thiazides. The lack of any demonstrable morbidity from thiazide-induced K⁺ depletion and the impressive prompt diuresis that these drugs produced at a low cost, however, carried the sulfonamide diuretics into a leadership position for treatment of hypertension . . . [Full Text of this Article]

This article has been cited by other articles:

				A. Ahmed, F. Zannad, T. E. Love, J. Tallaj, M. Gheorghiade, O. J. Ekundayo, and B. Pitt A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure Eur. Heart J., June 1, 2007; 28(11): 1334 - 1343. [Abstract] [Full Text] [PDF]

				B. Zimmermann, C. Plank, M. Konrad, W. Stohr, C. Gravou-Apostolatou, W. Rascher, and J. Dotsch Hydrochlorothiazide in CLDN16 mutation Nephrol. Dial. Transplant., August 1, 2006; 21(8): 2127 - 2132. [Abstract] [Full Text] [PDF]

				M. Christ, T. Klima, W. Grimm, H.-H. Mueller, and B. Maisch Prognostic significance of serum cholesterol levels in patients with idiopathic dilated cardiomyopathy Eur. Heart J., March 2, 2006; 27(6): 691 - 699. [Abstract] [Full Text] [PDF]

				Q. Wang, A. A. Domenighetti, T. Pedrazzini, and M. Burnier Potassium Supplementation Reduces Cardiac and Renal Hypertrophy Independent of Blood Pressure in DOCA/Salt Mice Hypertension, September 1, 2005; 46(3): 547 - 554. [Abstract] [Full Text] [PDF]

				J. M. McCurley, S. U. Hanlon, S.-k. Wei, E. F. Wedam, M. Michalski, and M. C. Haigney Furosemide and the progression of left ventricular dysfunction in experimental heart failure J. Am. Coll. Cardiol., September 15, 2004; 44(6): 1301 - 1307. [Abstract] [Full Text] [PDF]

				H. Bundgaard Potassium depletion improves myocardial potassium uptake in vivo Am J Physiol Cell Physiol, July 1, 2004; 287(1): C135 - C141. [Abstract] [Full Text] [PDF]

				P. E. G. Foglia, A. Bettinelli, C. Tosetto, C. Cortesi, L. Crosazzo, A. Edefonti, and M. G. Bianchetti Cardiac work up in primary renal hypokalaemia-hypomagnesaemia (Gitelman syndrome) Nephrol. Dial. Transplant., June 1, 2004; 19(6): 1398 - 1402. [Abstract] [Full Text] [PDF]

				C. Sierra and L. M Ruilope Review: Role of the selective aldosterone receptor blockers in arterial hypertension Journal of Renin-Angiotensin-Aldosterone System, March 1, 2004; 5(1): 23 - 25. [Abstract] [PDF]

				A. F. Hernandez and C. M. O'Connor Sparing a little may save a lot: Lessons from the Studies of Left Ventricular Dysfunction (SOLVD) J. Am. Coll. Cardiol., August 20, 2003; 42(4): 709 - 711. [Full Text] [PDF]